CAR T cells ignite antitumor immunity

Darya Alizadeh; Christine E Brown

doi:10.1016/j.it.2023.08.002

CAR T cells ignite antitumor immunity

Trends Immunol. 2023 Oct;44(10):748-750. doi: 10.1016/j.it.2023.08.002. Epub 2023 Aug 29.

Authors

Darya Alizadeh¹, Christine E Brown²

Affiliations

¹ Department of Hematology and Hematopoietic Cell Transplantation (T Cell Therapeutics Research Laboratories), City of Hope, Beckman Research Institute and Medical Center, Duarte, CA 91010, USA.
² Department of Hematology and Hematopoietic Cell Transplantation (T Cell Therapeutics Research Laboratories), City of Hope, Beckman Research Institute and Medical Center, Duarte, CA 91010, USA. Electronic address: cbrown@coh.org.

PMID: 37652814
DOI: 10.1016/j.it.2023.08.002

Abstract

Broadening immune responses through antigen spreading remains the 'Holy Grail' of cancer immunotherapy. A study by Ma and colleagues reveals that vaccine boosting of chimeric antigen receptor (CAR)-T cells in mice promotes endogenous immunity and elicits antigen spread to eliminate antigenically heterogenous solid tumors through a mechanism crucially dependent on interferon (IFN)γ.

Keywords: CAR T cell; IFNgamma; antigen spreading; chimeric antigen receptor (CAR); myeloid cells; tumor heterogeneity; vaccine.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Immunotherapy, Adoptive
Mice
Neoplasms* / therapy
Receptors, Antigen, T-Cell*
T-Lymphocytes

Substances

Receptors, Antigen, T-Cell